Gastrointestinal stromal tumours - sunitinib (TA179)
Sunitinib is recommended as a possible treatment for people with unresectable or metastatic malignant gastrointestinal stromal tumours if they have already tried imatinib treatment but it has not worked or was not suitable. The manufacturer of sunitinib has agreed to cover the cost of the drug for the first treatment cycle.
Treatment should be supervised by a specialist who is experienced in treating people with gastrointestinal stromal tumours.
This page was last updated: 13 February 2012
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA179 Sunitinib ar gyfer trin tiwmorau stromatig gastro-berfeddol: deall canllawiau NICE
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.